Contribution of monoamine oxidase inhibition to tobacco dependence: A review of the evidence

Nicotine and Tobacco Research

Volumn 18, Issue 5, 2016, Pages 509-523

  Hogg, Ron C ^a  

^a OmniScience SA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); BEFLOXATONE; BETA CARBOLINE; CLORGYLINE; HARMINE; LAZABEMIDE; MOCLOBEMIDE; NICOTINE; PHENELZINE; SELEGILINE; SEMBRAGILINE; TOBACCO SMOKE; TRANYLCYPROMINE; MONOAMINE OXIDASE INHIBITOR;

BINDING SITE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HEALTH HAZARD; HUMAN; IN VITRO STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SMOKING; SUBSTANCE ABUSE; TOBACCO; TOBACCO DEPENDENCE; BRAIN CHEMISTRY; ENZYMOLOGY;

BRAIN CHEMISTRY; HUMANS; MONOAMINE OXIDASE INHIBITORS; TOBACCO USE DISORDER;

EID: 84964950612     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntv245     Document Type: Review

References (120)

1. Berlin I, Anthenelli RM. Monoamine oxidases and tobacco smoking. Int J Neuropsychopharmacol. 2001;4(1):33-42. doi:10.1017/ S1461145701002188.
2. Berlin I, Spreux-Varoquaux O, Launay JM. Platelet monoamine oxidase B activity is inversely associated with plasma cotinine concentration. Nicotine Tob Res. 2000;2(3):243-246. doi:10.1080/14622200050147501.
3. Fowler JS, Logan J, Wang GJ, Volkow ND. Monoamine oxidase and cigarette smoking. Neurotoxicology. 2003;24(1):75-82. doi:10.1016/ S0161-813X(02)00109-2.
4. Lewis A, Miller JH, Lea RA. Monoamine oxidase and tobacco dependence. Neurotoxicology. 2007;28(1):182-195. doi:10.1016/j.neuro.2006.05.019.
5. SCENIHR (Scientific Committee on Emerging and Newly Identified Health Risks). Addictiveness and Attractiveness of Tobacco Additives. November 12, 2010. http://ec.europa.eu/health/scientific_committees/ emerging/docs/scenihr_o_029.pdf. Accessed April 23, 2015.
6. Explanatory Note for the Modifications of the SCENIHR Opinion on Addictiveness and Attractiveness of Tobacco Additives Following the Public Consultation on the Pre-consultation Opinion. November 12, 2010. http://ec.europa.eu/health/scientific_committees/emerging/docs/ scenihr_o_031_note.pdf. Accessed April 23, 2015.
7. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev. 2008;60(13- 14):1527-1533. doi:10.1016/j.addr.2008.06.002.
8. Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu Rev Neurosci. 1999;22:197-217. doi:10.1146/annurev.neuro.22.1.197.
9. Garrick NA, Murphy DL. Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain. Psychopharmacology (Berl). 1980;72(1):27-33. doi:10.1007/ BF00433804.
10. Glover V, Sandler M, Owen F, Riley GJ. Dopamine is a monoamine oxidase B substrate in man. Nature. 1977;265(5589):80-81. doi:10.1038/265080a0.
11. Shulman KI, Herrmann N, Walker SE. Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs. 2013;27(10):789- 797. doi:10.1007/s40263-013-0097-3.
12. Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of Parkinsonian patients treated with l-deprenyl. J Neurochem. 1986;46(5):1359-1365. doi:10.1111/j.1471-4159.1986.tb01747.x.
13. von Knorring L, Oreland L, Winblad B. Personality traits related to monoamine oxidase activity in platelets. Psychiatry Res. 1984;12(1):11-26. doi:10.1016/0165-1781(84)90134-3.
14. Oreland L, Damberg M, Hallman J, Garpenstrand H. Smoking only explains part of the associations between platelet monoamine oxidase activity and personality. J Neural Transm (Vienna). 2002;109(5-6):963- 975. doi:10.1007/s007020200079.
15. Oreland L, Hallman J. The correlation between platelet MAO activity and personality: short review of findings and a discussion on possible mechanisms. Prog Brain Res. 1995;106:77-84.
16. Fowler JS, Volkow ND, Wang GJ, et al. Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci USA. 1996;93(24):14065- 14069. www.pnas.org/content/93/24/14065.full. Accessed April 30, 2015.
17. Fowler JS, Logan J, Wang GJ, et al. Comparison of monoamine oxidase A in peripheral organs in nonsmokers and smokers. J Nucl Med. 2005;46(9):1414-1420. http://citeseerx.ist.psu.edu/viewdoc/download?d oi=10.1.1.329.369&rep=rep1&type=pdf. Accessed April 30, 2015
18. Villégier AS, Salomon L, Granon S, et al. Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine. Neuropsychopharmacology. 2006;31(8):1704-1713. doi:10.1038/ sj.npp.1300987.
19. Guillem K, Vouillac C, Azar MR, et al. Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats. Eur J Neurosci. 2006;24(12):3532-3540. doi:10.1111/j.1460-9568.2006.05217.x.
20. Fowler CJ, Mantle TJ, Tipton KF. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982;31(22):3555-3561. doi:10.1016/0006-2952(82)90575-5.
21. Olmos G, Gabilondo AM, Miralles A, Escriba PV, García-Sevilla JA. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Br J Pharmacol. 1993;108(3):597-603. doi:10.1111/j.1476-5381.1993.tb12848.x.
22. Leroy C, Bragulat V, Berlin I, et al. Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C] befloxatone. J Clin Psychopharmacol. 2009;29(1):86-88. doi:10.1097/ JCP.0b013e31819e98f.
23. Arib O, Rat P, Molimard R, Chait A, Faure P, de Beaurepaire R. Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons. Eur J Pharmacol. 2010;629(1-3):47-52. doi:10.1016/j.ejphar.2009.12.012.
24. Caille D, Bergis OE, Fankhauser C, et al. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. J Pharmacol Exp Ther. 1996;277(1):265-277.
25. Curet O, Damoiseau G, Aubin N, Sontag N, Rovei V, Jarreau FX. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. J Pharmacol Exp Ther. 1996;277(1):253-264.
26. Bacher I, Houle S, Xu X, et al. Monoamine oxidase A binding in the prefrontal and anterior cingulate cortices during acute withdrawal from heavy cigarette smoking. Arch Gen Psychiatry. 2011;68(8):817-826. doi:10.1001/archgenpsychiatry.2011.82.
27. Berlin I, Said S, Spreux-Varoquaux O, et al. A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers. Clin Pharmacol Ther. 1995;58(4):444-452. doi:10.1016/0009-9236(95)90058-6.
28. Berlin I, Zimmer R, Thiede HM, et al. Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990;30(6):805-816. doi:10.1111/j.1365-2125.1990.tb05445.x.
29. Stanford SC, Stanford BJ, Gillman PK. Risk of severe serotonin toxicity following co-administration of methylene blue and serotonin reuptake inhibitors: an update on a case report of postoperative delirium. J Psychopharmacol. 2010;24(10):1433-1438. doi:10.1177/0269881109105450.
30. Fowler JS, Volkow ND, Wang GJ, et al. Inhibition of monoamine oxidase B in the brains of smokers. Nature. 1996;379(6567):733-736. doi:10.1038/379733a0.
31. Fowler JS, Volkow ND, Wang GJ, et al. Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. J Addict Dis. 1998;17(1):23-34. doi:10.1300/J069v17n01_03.
32. Fowler JS, Wang GJ, Volkow ND, et al. Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence. Am J Psychiatry. 2000;157(11):1864-1866. http://ajp.psychiatryonline.org/doi/ full/10.1176/appi.ajp.157.11.1864. Accessed April 30, 2015.
33. Fowler JS, Logan J, Wang GJ, et al. Low monoamine oxidase B in peripheral organs in smokers. Proc Natl Acad Sci USA. 2003;100(20):11600- 11605. doi:10.1073/pnas.1833106100.
34. Fowler JS, Wang GJ, Volkow ND, et al. Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers. Nicotine Tob Res. 1999;1(4):325-329. doi:10.1080/14622299050011451.
35. George TP, Vessicchio JC, Termine A, Jatlow PI, Kosten TR, O'Malley SS. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry. 2003;53(2):136-143. doi:10.1016/ S0006-3223(02)01454-3.
36. Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction. 2003;98(10):1403- 1407. doi:10.1046/j.1360-0443.2003.00524.x.
37. Killen JD, Fortmann SP, Murphy GM Jr, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction. 2010;105(9):1660-1668. doi:10.1111/j.1360-0443.2010.03020.x.
38. Kahn R, Gorgon L, Jones K, et al. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res. 2012;14(3):377-382. doi:10.1093/ntr/ntr143.
39. Weinberger AH, Reutenauer EL, Jatlow PI, O'Malley SS, Potenza MN, George TP. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend. 2010;107(2-3):188-195. doi:10.1016/j.drugalcdep.2009.10.009.
40. Fowler JS, Volkow ND, Logan J, et al. Slow recovery of human brain MAO B after L-deprenyl (Selegeline) withdrawal. Synapse. 1994;18(2):86-93. doi:10.1002/syn.890180203.
41. Lee KC, Chen JJ. Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-537. www.ncbi.nlm.nih.gov/pmc/articles/PMC2656289/. Accessed April 30, 2015.
42. Houtsmuller EJ, Thornton JA, Stitzer ML. Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl). 2002;163(2):213-220. doi:10.1007/s00213-002-1152-9.
43. Bench CJ, Price GW, Lammertsma AA, et al. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327. Eur J Clin Pharmacol. 1991;40(2):169-173. doi:10.1007/ BF00280072.
44. Berlin I, Aubin HJ, Pedarriosse AM, Rames A, Lancrenon S, Lagrue G; Lazabemide in Smoking Cessation Study Investigators. Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Addiction. 2002;97(10):1347-1354. doi:10.1046/j.1360-0443.2002.00258.x.
45. Holford NH, Guentert TW, Dingemanse J, Kettler R. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B. Br J Clin Pharmacol. 1994;37(6):553-557. doi:10.1111/j.1365-2125.1994.tb04303.x.
46. Berlin I, Hunneyball IM, Greiling D, Jones SP, Fuder H, Stahl HD. A selective reversible monoamine oxidase B inhibitor in smoking cessation: effects on its own and in association with transdermal nicotine patch. Psychopharmacology (Berl). 2012;223(1):89-98. doi:10.1007/ s00213-012-2692-2.
47. Evotec. Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302. 2008. www.evotec.com/uploads/cms_article/1547/Phase_I_ Safety_and_Tolerability_Study_with_EVT_302.pdf. Accessed April 23, 2015.
48. Villégier AS, Blanc G, Glowinski J, Tassin JP. Transient behavioral sensitization to nicotine becomes long-lasting with monoamine oxidases inhibitors. Pharmacol Biochem Behav. 2003;76(2):267-274. doi:10.1016/ S0091-3057(03)00223-5.
49. Villégier AS, Salomon L, Blanc G, Godeheu G, Glowinski J, Tassin JP. Irreversible blockade of monoamine oxidases reveals the critical role of 5-HT transmission in locomotor response induced by nicotine in mice. Eur J Neurosci. 2006;24(5):1359-1365. doi:10.1111/j.1460-9568.2006.05011.x.
50. Villégier AS, Lotfipour S, McQuown SC, Belluzzi JD, Leslie FM. Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology. 2007;52(6):1415-1425. doi:10.1016/j.neuropharm.2007.02.001.
51. Guillem K, Vouillac C, Azar MR, et al. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J Neurosci. 2005;25(38):8593-8600. doi:10.1523/jneurosci.2139-05.2005.
52. Guillem K, Vouillac C, Koob GF, Cador M, Stinus L. Monoamine oxidase inhibition dramatically prolongs the duration of nicotine withdrawal- induced place aversion. Biol Psychiatry. 2008;63(2):158-163. doi:10.1016/j.biopsych.2007.04.029.
53. Anthenelli RM, Tipp J, Li TK, et al. Platelet monoamine oxidase activity in subgroups of alcoholics and controls: results from the Collaborative Study on the Genetics of Alcoholism. Alcohol Clin Exp Res. 1998;22(3):598- 604. doi:10.1111/j.1530-0277.1998.tb04298.x.
54. Anthenelli RM, Smith TL, Craig CE, Tabakoff B, Schuckit MA. Platelet monoamine oxidase activity levels in subgroups of alcoholics: diagnostic, temporal, and clinical correlates. Biol Psychiatry. 1995;38(6):361-368. doi:10.1016/0006-3223(94)00298-H.
55. Whitfield JB, Pang D, Bucholz KK, et al. Monoamine oxidase: associations with alcohol dependence, smoking and other measures of psychopathology. Psychol Med. 2000;30(2):443-454. https://keppel.qimr.edu.au/contents/ publications/staff/CV265.pdf. Accessed April 30, 2015.
56. Snell LD, Glanz J, Tabakoff B; WHO/ISBRA Study on State and Trait Markers ofAlcohol Use and Dependence Investigators. Relationships between effects of smoking, gender, and alcohol dependence on platelet monoamine oxidase-B: activity, affinity labeling, and protein measurements. Alcohol Clin Exp Res. 2002;26(7):1105-1113. doi:10.1111/j.1530-0277.2002.tb02645.x.
57. Berggren U, Eriksson M, Fahlke C, Blennow K, Balldin J. Different effects of smoking or use of smokeless tobacco on platelet MAO-B activity in type 1 alcohol-dependent subjects. Alcohol Alcohol. 2007;42(3):267-271. doi:10.1093/alcalc/agm031.
58. Norman TR, Chamberlain KG, French MA. Platelet monoamine oxidase: low activity in cigarette smokers. Psychiatry Res. 1987;20(3):199-205. doi:10.1016/0165-1781(87)90079-5.
59. Norman TR, Chamberlain KG, French MA, Burrows GD. Platelet monoamine oxidase activity and cigarette smoking. J Affect Disord. 1982;4(1):73-77. doi:10.1016/0165-0327(82)90021-0.
60. Harro M, Eensoo D, Kiive E, et al. Platelet monoamine oxidase in healthy 9- and 15-years old children: the effect of gender, smoking and puberty. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25(8):1497-1511. doi:10.1016/S0278-5846(01)00212-3.
61. Launay JM, Del Pino M, Chironi G, et al. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS One. 2009;4(11):e7959. doi:10.1371/journal.pone.0007959.
62. Berlin I, Said S, Spreux-Varoquaux O, Olivares R, Launay JM, Puech AJ. Monoamine oxidase A and B activities in heavy smokers. Biol Psychiatry. 1995;38(11):756-761. doi:10.1016/0006-3223(95)00084-4.
63. Oreland L, Fowler CJ, Schalling D. Low platelet monoamine oxidase activity in cigarette smokers. Life Sci. 1981;29(24):2511-2518. doi:10.1016/0024-3205(81)90706-2.
64. Fowler JS, MacGregor RR, Wolf AP, et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science. 1987;235(4787):481-485. doi:10.1126/science.3099392.
65. Freedman NM, Mishani E, Krausz Y, et al. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET. J Nucl Med. 2005;46(10):1618-1624. http://jnm.snmjournals.org/content/46/10/1618.full. Accessed April 30, 2015.
66. Chen K, Wu HF, Shih JC. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem. 1993;61(1):187-190. doi:10.1111/j.1471-4159.1993.tb03554.x.
67. Harro J, Fischer K, Vansteelandt S, Harro M. Both low and high activities of platelet monoamine oxidase increase the probability of becoming a smoker. Eur Neuropsychopharmacol. 2004;14(1):65-69. doi:10.1016/ S0924-977X(03)00062-2.
68. McKinney EF, Walton RT, Yudkin P, et al. Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers. Pharmacogenetics. 2000;10(6):483-491.
69. Rose JE, Behm FM, Ramsey C, Ritchie JC Jr. Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms. Nicotine Tob Res. 2001;3(4):383-390. doi:10.1080/14622200110087277.
70. Gilbert DG, Zuo Y, Browning RA, et al. Platelet monoamine oxidase B activity changes across 31 days of smoking abstinence. Nicotine Tob Res. 2003;5(6):813-819. doi:10.1080/14622200310001614575.
71. Blum K, Sheridan PJ, Wood RC, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med. 1996;89(7):396-400.
72. Jarvis MJ, Tunstall-Pedoe H, Feyerabend C, Vesey C, Saloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health. 1987;77(11):1435-1438. doi:10.2105/ AJPH.77.11.1435.
73. Hauptmann N, Shih JC. 2-Naphthylamine, a compound found in cigarette smoke, decreases both monoamine oxidase A and B catalytic activity. Life Sci. 2001;68:1231-1241. doi:10.1016/S0024-3205(00)01022-5.
74. Khalil AA, Steyn S, Castagnoli N Jr. Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. Chem Res Toxicol. 2000;13(1):31-35. doi:10.1021/tx990146f.
75. Carr LA, Basham JK. Effects of tobacco smoke constituents on MPTPinduced toxicity and monoamine oxidase activity in the mouse brain. Life Sci. 1991;48(12):1173-1177. doi:10.1016/0024-3205(91)90455-K.
76. Yu PH, Boulton AA. Irreversible inhibition of monoamine oxidase by some components of cigarette smoke. Life Sci. 1987;41(6):675-682. doi:10.1016/0024-3205(87)90446-2.
77. Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun. 2005;326(2):378-386. doi:10.1016/j.bbrc.2004.11.033.
78. Lewis AJ, Truman P, Hosking MR, Miller JH. Monoamine oxidase inhibitory activity in tobacco smoke varies with tobacco type. Tob Control. 2012;21(1):39-43. doi:10.1136/tc.2010.040287.
79. Costello MR, Reynaga DD, Mojica CY, Zaveri NT, Belluzzi JD, Leslie FM. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology. 2014;39(8):1843-1851. doi:10.1038/npp.2014.31.
80. Rommelspacher H, Meier-Henco M, Smolka M, Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur J Pharmacol. 2002;441(1-2):115-125. doi:10.1016/ S0014-2999(02)01452-8.
81. Talhout R, Opperhuizen A, van Amsterdam JG. Role of acetaldehyde in tobacco smoke addiction. Eur Neuropsychopharmacol. 2007;17(10):627- 636. doi:10.1016/j.euroneuro.2007.02.013.
82. Mendez-Alvarez E, Soto-Otero R, Sanchez-Sellero I, Lopez-Rivadulla Lamas M. Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke. Life Sci. 1997;60(19):1719-1727. doi:10.1016/S0024-3205(97)00114-8.
83. Khalil AA, Davies B, Castagnoli N Jr. Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. Bioorg Med Chem. 2006;14(10):3392-3398. doi:10.1016/j.bmc.2005.12.057.
84. Castagnoli K, Steyn SJ, Magnin G, et al. Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase. Neurotox Res. 2002;4(2):151-160. doi:10.1080/10298420290015854.
85. Seeman JI, Dixon M, Haussmann HJ. Acetaldehyde in mainstream tobacco smoke: formation and occurrence in smoke and bioavailability in the smoker. Chem Res Toxicol. 2002;15(11):1331-1350. doi:10.1021/ tx020069f.
86. United States Food and Drug Administration. Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke: Established List. March 2012. www.fda.gov/TobaccoProducts/ GuidanceComplianceRegulatoryInformation/ucm297786.htm. Accessed April 23, 2015.
87. Tobacco Products Scientific Advisory Committee. Draft Initial H/PH Constituents and Their Association With Selected Tobacco Product- Related Diseases. Gaithersburg, MD; August 30, 2010. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ TobaccoProductsScientificAdvisoryCommittee/UCM221805.pdf.Accessed April 23, 2015.
88. Myers WD, Ng KT, Singer G. Intravenous self-administration of acetaldehyde in the rat as a function of schedule, food deprivation and photoperiod. Pharmacol Biochem Behav. 1982;17(4):807-811. doi:10.1016/0091-3057(82)90364-1.
89. Amit Z, Brown ZW, Rockman GE. Possible involvement of acetaldehyde, norepinephrine and their tetrahydroisoquinoline derivatives in the regulation of ethanol seld-administration. Drug Alcohol Depend. 1977;2(5-6):495-500. doi:10.1016/0376-8716(77)90049-7.
90. Brown ZW, Amit Z, Rockman GE. Intraventricular self-administration of acetaldehyde, but not ethanol, in naive laboratory rats. Psychopharmacology (Berl). 1979;64(3):271-276. doi:10.1007/ BF00427509.
91. McBride WJ, Li TK, Deitrich RA, Zimatkin S, Smith BR, Rodd-Henricks ZA. Involvement of acetaldehyde in alcohol addiction. Alcohol Clin Exp Res. 2002;26(1):114-119. doi:10.1111/j.1530-0277.2002.tb02439.x.
92. Rodd-Henricks ZA, Melendez RI, Zaffaroni A, Goldstein A, McBride WJ, Li TK. The reinforcing effects of acetaldehyde in the posterior ventral tegmental area of alcohol-preferring rats. Pharmacol Biochem Behav. 2002;72(1-2):55-64. doi:10.1016/S0091-3057(01)00733-X.
93. Philip Morris. Table of Contents for the Philip Morris Behavioral Research Program. Tobacco Industry Documents: Philip Morris; Bates Number: 2021423427-3461. 1992. http://legacy.library.ucsf.edu/action/ document/page?tid=lum88d00. Accessed April 23, 2015.
94. Belluzzi JD, Wang R, Leslie FM. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology. 2005;30(4):705-712. doi:10.1038/sj.npp.1300586.
95. McLaughlin SD, Scott BK, Peterson CM. The effect of cigarette smoking on breath and whole blood-associated acetaldehyde. Alcohol. 1990;7(4):285-287. doi:10.1016/0741-8329(90)90083-O.
96. Poindexter EH. The isolation of harmane and norharmane from tobacco and cigarette smoke. Phytochemistry. 1962;1:215-221. doi:10.1016/ S0031-9422(00)82825-3.
97. Totsuka Y, Ushiyama H, Ishihara J, et al. Quantification of the comutagenic beta-carbolines, norharman and harman, in cigarette smoke condensates and cooked foods. Cancer Lett. 1999;143(2):139-143. doi:10.1016/S0304-3835(99)00143-3.
98. Fekkes D, Bode WT. Occurrence and partition of the beta-carboline norharman in rat organs. Life Sci. 1993;52(25):2045-2054. doi:10.1016/0024-3205(93)90689-Z.
99. Breyer-Pfaff U, Wiatr G, Stevens I, Gaertner HJ, Mundle G, Mann K. Elevated norharman plasma levels in alcoholic patients and controls resulting from tobacco smoking. Life Sci. 1996;58(17):1425-1432. doi:10.1016/0024-3205(96)00112-9.
100. Spijkerman R, van den Eijnden R, van de Mheen D, Bongers I, Fekkes D. The impact of smoking and drinking on plasma levels of norharman. Eur Neuropsychopharmacol. 2002;12(1):61-71. doi:10.1016/ S0924-977X(01)00143-2.
101. Rommelspacher H, Büchau C, Weiss J. Harman induces preference for ethanol in rats: is the effect specific for ethanol? Pharmacol Biochem Behav. 1987;26(4):749-755. doi:10.1016/0091-3057(87)90607-1.
102. Bryant MS, Vineis P, Skipper PL, Tannenbaum SR. Hemoglobin adducts of aromatic amines: associations with smoking status and type of tobacco. Proc Natl Acad Sci USA. 1988;85(24):9788-9791. www.pnas.org/content/85/24/9788.full.pdf. Accessed April 30, 2015.
103. Pfau W, Skog K. Exposure to beta-carbolines norharman and harman. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;802(1):115-126. doi:10.1016/j.jchromb.2003.10.044.
104. Herraiz T, Chaparro C. Human monoamine oxidase enzyme inhibition by coffee and beta-carbolines norharman and harman isolated from coffee. Life Sci. 2006;78(8):795-802. doi:10.1016/j.lfs.2005.05.074.
105. Herraiz T. Relative exposure to beta-carbolines norharman and harman from foods and tobacco smoke. Food Addit Contam. 2004;21(11):1041- 1050. doi:10.1080/02652030400019844.
106. George TP, Weinberger AH. Monoamine oxidase inhibition for tobacco pharmacotherapy. Clin Pharmacol Ther. 2008;83(4):619-621. doi:10.1038/sj.clpt.6100474.
107. Berlin, I. Monoamine oxidase inhibitors for smoking cessation medication. In: George TP, ed. Medication Treatments for Nicotine Dependence. Boca Raton, FL: CRC Press; 2007:110-119.
108. Hughes JR, Stead LF, Hartmann-Boyce J, Cahill K, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2014;1:CD000031. doi:10.1002/14651858.CD000031.pub4.
109. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997;282(3):1608-1614. http://jpet.aspetjournals.org/content/ 282/3/1608.long. Accessed April 30, 2015.
110. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos. 1996;24(11):1212-1217.
111. Siu EC, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. J Pharmacol Exp Ther. 2008;324(3):992-999. doi:10.1124/ jpet.107.133900.
112. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos. 2001;29(6):897-902. http:// dmd.aspetjournals.org/content/29/6/897.full. Accessed April 30, 2015.
113. Citrome L, Goldberg JF, Portland KB. Placing transdermal selegiline for major depressive disorder into clinical context: number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2013;151(2):409-417. doi:10.1016/j.jad.2013.06.027.
114. Frieling H, Bleich S. Tranylcypromine: new perspectives on an "old" drug. Eur Arch Psychiatry Clin Neurosci. 2006;256(5):268-273. doi:10.1007/s00406-006-0660-8.
115. McDaniel KD. Clinical pharmacology of monoamine oxidase inhibitors. Clin Neuropharmacol. 1986;9(3):207-234.
116. Arnold MM, Loughlin SE, Belluzzi JD, Leslie FM. Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine. Neuropharmacology. 2014;85:293-304. doi:10.1016/j.neuropharm.2014.05.035.
117. Malin DH, Moon WD, Goyarzu P, et al. Inhibition of monoamine oxidase isoforms modulates nicotine withdrawal syndrome in the rat. Life Sci. 2013;93(12-14):448-453. doi:10.1016/j.lfs.2013.08.006.
118. Nardil United Kingdom Summary of Product Characteristics. 2014. www.medicines.org.uk/emc/medicine/18541/SPC/Nardil+tablets/. Accessed April 23, 2015.
119. Tranylcypromine 10 mg Tablets United Kingdom Summary of Product Characteristics. 2014. www.medicines.org.uk/emc/medicine/25577/ SPC/Tranylcypromine+10+mg+Tablets/. Accessed April 23, 2015.
120. Rose JE, Corrigall WA. Nicotine self-administration in animals and humans: similarities and differences. Psychopharmacology (Berl). 1997;130(1):28-40.